Candriam SCA’s ORIX IX Stock Holding History

Candriam SCA’s Portfolio IX Stock Details IX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-65	Closed	-$1K	–	798
2022 Q1	$1K	Buy	+65	New	+$1.33K	﹤0.01%	800
2021 Q4	–	Sell	-55	Closed	-$1K	–	832
2021 Q3	$1K	Buy	+55	New	+$1.01K	﹤0.01%	870
2019 Q3	–	Sell	-105	Closed	-$1.57M	–	775
2019 Q2	$1.57M	Buy	105 +80	+320%	+$1.15K	0.02%	567
2019 Q1	$359K	Sell	25 -5	-17%	-$74	﹤0.01%	752
2018 Q4	$0	Buy	+30	New	+$470	﹤0.01%	832

Other funds holding IX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TAM

Todd Asset Management Louisville, Kentucky $5.63B AUM 45.28% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

OSAM

O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

EGA

Eagle Global Advisors Houston, Texas $3.02B AUM 34.37% 1-Year Est. Return

Candriam SCA's IX Position: Q2 2022 in Review

Candriam SCA sold out of ORIX (IX) in Q2 2022, closing a stake of 65 shares — an estimated $1K sold.

Candriam SCA first reported a position in IX in Q4 2018 and held it in 5 quarters. The position peaked at $1.57M in Q2 2019. 139 funds tracked by Wall St. Rank hold IX as of Q2 2022.

Candriam SCA reported no remaining ORIX position as of Q2 2022 after selling out during the quarter.
Candriam SCA sold 65 ORIX shares in Q2 2022, an estimated $1K.
Candriam SCA first reported a position in ORIX in Q4 2018 and held it in 5 quarters.
Candriam SCA's ORIX position peaked at $1.57M in Q2 2019.
139 funds tracked by Wall St. Rank held ORIX as of Q2 2022.

Based on Candriam SCA's 13F filing for Q2 2022, filed 3 Aug 2022.